Background:A 1-year, single-center trial demonstrated that monitoring and preemptive of immunosuppression reduction were associated with resolution of viremia.Our 5-year prospective subsequent study was conducted to determine the long-term patient/graft survival and outcome of BK viremia and BK virus-associated nephropathy (BKVAN) in renal transplant recipients under the impact of intensive monitoring and reduction of maintenance immunosuppression. Methods:Quantitative BK virus (BKV) DNA surveillance in plasma/urine and cytological test in urine were performed at 1, 3, 6, 9, and 12 months after transplantation in 229 kidney recipients.Patients with BK viremia and BKVAN treated with 30% to 50% reduction in doses of tacrolimus (Tac) or/and mycophenolate mofetil(MMF) without antiviral therapy and were monitored for BKV every 3-6 months. All the patients were followed for 5 years. Results:Overall 5-year patient survival was 95.6% and graft survival was 92.1%. There were no differences in patient/graft survival, renal function, and rejection rate by presence of decoy cells, BK-viruria, viremia, or BKVAN. Multivariate analysis showed that Tac(OR, 2.9; P=0.032)and deceased kidney donation(OR, 2.1; P=0.071) were risk factors for BK viremia. After reduction of immunosuppression, viremia (n=38) resolved in 100%, without increased acute rejection. In the duration of follow-up 2-5 posttransplant years, BK viremia was not observed again in the BK viremic patients (n=30) without BKVAN. BKVAN was diagnosed in 7 cases(3.1%). The treatment of immunosuppression reduction was effective. All the BKVAN patients cleared viremia with a mean time of 5.9 months (range 1-15 months). Three of 7 BKVAN patients cleared viruria. A repeated renal biopsy was performed in two patients and revealed resolving BKVAN. There was no decline in estimated glomerular filtration rate over time from1 month(53.1mL/min) to 5 years(58.5mL/min) after transplantation (P=0.960). Conclusions:Monitoring and preemptive of immunosuppression reduction resulted in the successful resolution of BK viremia, showed effective in BKVAN recipients at the early stage with excellent graft survival and renal function at 5-years.
Aim: To investigate the possibility of pig endogenous retrovirus transmission in the type 1 diabetic recipients 13 years after islet xenotransplantation Material and methods: In 1999, three type 1 diabetic patients underwent laparoscopic islet xenotransplantation in our institute. Microencapsulated neonatal pig islet cells were transplanted into the patient peritoneal cavity via laparoscopy with the dosage of 10,000IEQ/kg. The dosage of insulin used was decreased by 63%, 40% and 53%, respectively after transplantation for a long peroid. No evidence of PERV infection was observed in the two-year follow-up after transplantation. Thirteen years later, they were recruited in this study for the PERV detection as a research group. Three volunteers and the porcine tissues were used as control group. Genomic DNA and RNA were isolated from the PBMC samples from the recipients and the volunteers or porcine tissues by using the DNeasyTM Tissue Kit. PCR and RT-PCR were used to detect the PERV by using the specific promoter. Results: Specific PERV DNA and RNA could not be detected in the recipient and volunteers, while which were observed in the pig tissues, including blood, liver and spleen. Conclusion: Although PERV could be detected from the pigs tissues, porcine islet xenotransplantation is a safe method to cure type 1 diabetic patients, and no evidence of PERV infection in recipients at 13 years after islet xenotransplantation.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
